Hot Keywords
Charcot-Marie-Tooth Disease Rare Diseases Genome Project DNA Damage Multiple myeloma Prostate Cancer Oncolytic Viruses Epilepsy Breast Cancer mitochondrial disease Long QT syndrome

Topic: RNA in Prostate Cancer and Renal Cell Carcinoma

A special issue of Journal of Translational Genetics and Genomics

ISSN 2578-5281 (Online)

Submission deadline: 31 Jul 2022

Guest Editor(s)

  • Dr. Sharanjot Saini
    Department of Biochemistry and Molecular Biology, Augusta University, Augusta, GA, USA.

    Website | E-mail

Special Issue Introduction

Prostate cancer is the second leading cause of death among men with most of the mortality resulting from aggressive disease. Increasing evidence suggests that prostate cancer transcriptome is highly heterogeneous, with RNAs playing a fundamental role in the etiology of prostate cancer. Classes of RNAs include coding and non-coding RNAs (such as micoRNAs (miRNAs), long-non-coding RNAs (lncRNAs) and circular RNAs). These RNAs have intriguing properties with important regulatory functions in prostate cancer and have been implicated in initiation, progression and metastasis via their gene regulatory roles. Similarly, RNAs have been implicated in renal cell carcinoma (RCC), the most prevalent form of kidney cancer. Clinically, RNAs are promising biomarkers and therapeutic targets in prostate and renal cancers. Recent work has evaluated the clinical applications of RNAs in liquid biopsies of these cancers. Furthermore, recent technological advances such as spatial transcriptomics and ability to study RNA-protein interactions have opened up exciting new avenues for RNA research. In addition, recent work has evaluated the clinical applications of these RNAs in RNA-based therapies for these malignancies. In this review, we summarize recent findings on RNAs in prostate cancer and renal cell carcinoma and highlight their potential clinical utility as novel biomarkers and therapeutic targets.


RNA, prostate cancer, renal cell carcinoma, spatial transcriptomics, RNA-protein interactions, therapeutic targets

Submission Deadline

31 Jul 2022

Submission Information

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to
For Online Submission, please login at
Submission Deadline: 31 Jul 2022
Contacts: Jixiang Zhao, Assistant Editor,

Published Articles

© 2016-2023 OAE Publishing Inc., except certain content provided by third parties